These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8675555)

  • 1. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend.
    Peters AL; Davidson MB
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2423-7. PubMed ID: 8675555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycemia in hospitalized patients treated with sulfonylureas.
    Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
    Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
    Osei K; Falko JM
    Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
    Welle S; Nair KS; Lockwood D
    J Clin Endocrinol Metab; 1988 Mar; 66(3):593-7. PubMed ID: 3127418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
    Osei K; O'Dorisio TM; Falko JM
    Am J Med; 1984 Dec; 77(6):1002-9. PubMed ID: 6439036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
    Landstedt-Hallin L; Adamson U; Lins PE
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3140-5. PubMed ID: 10487677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
    Umpierrez GE; Clark WS; Steen MT
    Diabetes Care; 1997 Apr; 20(4):479-83. PubMed ID: 9096964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
    Loomba-Albrecht LA; Glaser NS; Styne DM; Bremer AA
    Clin Ther; 2009 Apr; 31(4):816-20. PubMed ID: 19446154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal dose glyburide therapy in markedly symptomatic patients with type II diabetes: a new use for an old friend.
    Block MB
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4179. PubMed ID: 8923885
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of glipizide and glyburide in a health maintenance organization.
    Noyes MA; Carter BL; Helling DK; McCormick WC; Ramirez R
    Ann Pharmacother; 1992 Oct; 26(10):1215-20. PubMed ID: 1421641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
    Lardinois CK; Liu GC; Reaven GM
    Arch Intern Med; 1985 Jun; 145(6):1028-32. PubMed ID: 3923961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy.
    Grunberger G
    Diabetes Care; 1992 May; 15(5):696-9. PubMed ID: 1516489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
    Riddle M; Hart J; Bingham P; Garrison C; McDaniel P
    Am J Med Sci; 1992 Mar; 303(3):151-6. PubMed ID: 1595776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus.
    Aguilar-Salinas CA; Muñoz-Hernandez LL; Cobos-Bonilla M; Ramírez-Márquez MR; Ordoñez-Sanchez ML; Mehta R; Medina-Santillan R; Tusie-Luna MT
    Metabolism; 2013 May; 62(5):638-41. PubMed ID: 23273975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.